A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Haemangiosarcoma; Kaposi's sarcoma; Leiomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms Axi-STS
- 02 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 11 Feb 2016 Accrual to date is 100% according to the United Kingdom Clinical Research Network record.
- 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.